Physician profile
John A Whitney
NPI 1205240637
$2,609.23
in general payments reported to CMS, 2019-2025
36 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,046 · 2020: $171 · 2021: $394 · 2022: $637 · 2023: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $362.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.07 | 2021-2023 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $235.16 | 2019-2023 | Farxiga |
| Vifor Pharma, INC. | $200.86 | 2019-2022 | |
| Novo Nordisk INC | $199.15 | 2019-2022 | |
| Pfizer INC. | $149.98 | 2019-2023 | |
| Glaxosmithkline, LLC. | $147.27 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $141.75 | 2019-2023 | |
| Amgen INC. | $122.48 | 2019-2023 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $119.41 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.30 | 2019-2023 | Jardiance |
| Mallinckrodt Hospital Products INC. | $71.17 | 2021-2023 | Acthar |
| Biohaven Pharmaceutical Holding Company LTD. | $53.06 | 2022 | |
| Amarin Pharma, INC. | $41.61 | 2019 | |
| Allergan, INC. | $40.85 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38.83 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.43 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.96 | 2019-2023 | Gattex |
| Ironshore Pharmaceuticals INC. | $33.13 | 2019-2020 | |
| Dexcom, INC. | $32.91 | 2022 | |
| Opko Pharmaceuticals, LLC | $31.39 | 2019-2023 | Rayaldee |
| Esperion Therapeutics, INC. | $30.98 | 2022 | |
| Mylan Specialty L.P. | $30.82 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $30.65 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $29.26 | 2019 | |
| Fresenius USA Marketing, INC. | $29.02 | 2019-2023 | Korsuva, Velphoro |
| Ultragenyx Pharmaceutical INC. | $27.84 | 2019-2021 | |
| Exact Sciences Corporation | $26.13 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $20.73 | 2019 | |
| Merck Sharp & Dohme LLC | $18.02 | 2021 | |
| Neos Therapeutics, LP | $18.01 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.63 | 2021 | |
| Organon LLC | $17.43 | 2023 | Nexplanon |
| Covis Pharma Gmbh | $15.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.25 | 2021 | |
| Shire North American Group INC | $13.60 | 2019 | |
| Horizon Therapeutics Plc | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.